Welcome to our dedicated page for IPCI news (Ticker: IPCI), a resource for investors and traders seeking the latest updates and insights on IPCI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IPCI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IPCI's position in the market.
Intellipharmaceutics International reported a net loss of $5.15 million for the year ending November 30, 2021, compared to $3.39 million in 2020. Revenue fell to $0 from $1.4 million, primarily due to decreased licensing revenues from generic Focalin XR. The company received Health Canada approval for generic Pristiq and FDA approval for Dexmethylphenidate capsules, which may enhance their product offerings. However, termination of exclusive licensing agreements limits revenue potential from these products.
Cash rose to $772K thanks to a private placement.
